Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on Eve Holding Inc. (EVEX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Joby Aviation Inc (JOBY)
-
Cantor Fitzgerald Reiterates Overweight Rating on Archer Aviation Inc. (ACHR)
-
Cantor Fitzgerald Starts Tyler Tech (TYL) at Neutral
-
Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM)
-
Cantor Fitzgerald Starts SPS Commerce (SPSC) at Overweight
-
Cantor Fitzgerald Starts Q2 Holdings (QTWO) at Overweight
-
Cantor Fitzgerald Starts BlackLine (BL) at Neutral
-
Cantor Fitzgerald Starts Agilysys Inc (AGYS) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Zai Lab (ZLAB)
-
Cantor Fitzgerald Starts Klaviyo Inc (KVYO) at Overweight
-
Cantor Fitzgerald Starts HubSpot Inc (HUBS) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Bicara Therapeutics Inc (BCAX)
-
Cantor Fitzgerald Starts Freshworks Inc (FRSH) at Overweight
-
Cantor Fitzgerald Starts Sprinklr Inc (CXM) at Neutral
-
Cantor Fitzgerald Starts salesforce.com (CRM) at Overweight
-
Cantor Fitzgerald Starts Braze Inc (BRZE) at Overweight
-
Cantor Fitzgerald Starts Sprout Social Inc. (SPT) at Neutral, 'Margin gains and FCF conversion are improving with plenty of upside remaining from here'
-
Trevi Therapeutics (TRVI) Announces Proposed $100M Share Offering
-
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
-
ASP Isotopes Inc. Announces Pricing of $50 Million Underwritten Registered Direct Offering of Common Stock
-
Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)
-
Cantor Fitzgerald Reiterates Overweight Rating on Bicara Therapeutics Inc (BCAX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Immatics (IMTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
AxoGen, Inc. (AXGN) PT Lowered to $23 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Elutia (ELUT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Cerus (CERS)
-
Cantor Fitzgerald Reiterates Overweight Rating on TriSalus Life Sciences, Inc. (TLSI)
-
Trump Media & Technology Group (DJT) Closes Bitcoin Treasury Deal
-
Trump Media Closes Bitcoin Treasury Deal
-
Form NPORT-P CANTOR FITZGERALD INFRAS For: Mar 31
-
Cantor Fitzgerald Reports Key Takeaways from Call With RadioMedia CEO
-
Cantor Fitzgerald reports key Takeaways from call with RadioMedia CEO
-
Cantor Fitzgerald Reiterates Neutral Rating on Marvell (MRVL)
-
Zscaler (ZS) PT Raised to $290 at Cantor Fitzgerald
-
Elastic NV. (ESTC) PT Lowered to $92 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on CrowdStrike Holdings (CRWD)
-
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
-
Cantor Fitzgerald Asset Management to Launch Gold Protected Bitcoin Fund
-
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
-
Intellia stock tumbles on safety concerns
-
Cantor Fitzgerald Reiterates Overweight Rating on MindMed (MNMD)
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vera Therapeutics (VERA)
-
Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA)
-
Cantor Fitzgerald Reiterates Overweight Rating on SentinelOne Inc (S)
-
Cantor Fitzgerald Reiterates Overweight Rating on Intellia Therapeutics (NTLA)
-
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC)

